GAITHERSBURG, Md. (WTVO) — A fourth COVID-19 vaccine could get authorization for emergency use in the U.S. as early as next month.
Novavax submitted its final data to the FDA. A late-stage trial showed that it was more than 90% effective against a variety of COVID variants, including delta.
However, the Maryland-based company is still working to develop a vaccine specifically for omicron.